Year |
Citation |
Score |
2019 |
Wang Y, Grainger DW. Lyophilized liposome-based parenteral drug development: Reviewing complex product design strategies and current regulatory environments. Advanced Drug Delivery Reviews. PMID 30898571 DOI: 10.1016/J.Addr.2019.03.003 |
0.44 |
|
2014 |
Wang Y, Liu J, Zhang J, Wang L, Chan J, Wang H, Jin Y, Yu L, Grainger DW, Ying W. A cell-based pharmacokinetics assay for evaluating tubulin-binding drugs. International Journal of Medical Sciences. 11: 479-87. PMID 24688312 DOI: 10.7150/Ijms.8340 |
0.503 |
|
2014 |
Ying W, Liu J, Tsang KY, Wang L, Yin H, Bai H, Wang Y, Wang L, Niitsu Y. Abstract 4578: A novel polymer-anticancer drug micelle formulation showing enhanced efficacy over Abraxane Cancer Research. 74: 4578-4578. DOI: 10.1158/1538-7445.Am2014-4578 |
0.307 |
|
2014 |
Wang Y, Grainger DW. Barriers to advancing nanotechnology to better improve and translate nanomedicines Frontiers of Chemical Science and Engineering. 8: 265-275. DOI: 10.1007/S11705-014-1442-X |
0.497 |
|
2013 |
Wang Y, Grainger DW. Developing siRNA therapies to address osteoporosis. Therapeutic Delivery. 4: 1239-46. PMID 24116909 DOI: 10.4155/Tde.13.85 |
0.53 |
|
2012 |
Wang Y, Tran KK, Shen H, Grainger DW. Selective local delivery of RANK siRNA to bone phagocytes using bone augmentation biomaterials. Biomaterials. 33: 8540-7. PMID 22951320 DOI: 10.1016/J.Biomaterials.2012.07.039 |
0.529 |
|
2012 |
Yang D, Liu X, Jiang X, Liu Y, Ying W, Wang H, Bai H, Taylor WD, Wang Y, Clamme JP, Co E, Chivukula P, Tsang KY, Jin Y, Yu L. Effect of molecular weight of PGG-paclitaxel conjugates on in vitro and in vivo efficacy. Journal of Controlled Release : Official Journal of the Controlled Release Society. 161: 124-31. PMID 22521595 DOI: 10.1016/J.Jconrel.2012.04.010 |
0.303 |
|
2012 |
Wang Y, Grainger DW. RNA therapeutics targeting osteoclast-mediated excessive bone resorption. Advanced Drug Delivery Reviews. 64: 1341-57. PMID 21945356 DOI: 10.1016/J.Addr.2011.09.002 |
0.529 |
|
2011 |
Wang Y, Panasiuk A, Grainger DW. Small interfering RNA knocks down the molecular target of alendronate, farnesyl pyrophosphate synthase, in osteoclast and osteoblast cultures. Molecular Pharmaceutics. 8: 1016-24. PMID 21186792 DOI: 10.1021/Mp100374N |
0.536 |
|
2010 |
Takahashi H, Wang Y, Grainger DW. Device-based local delivery of siRNA against mammalian target of rapamycin (mTOR) in a murine subcutaneous implant model to inhibit fibrous encapsulation. Journal of Controlled Release : Official Journal of the Controlled Release Society. 147: 400-7. PMID 20727922 DOI: 10.1016/J.Jconrel.2010.08.019 |
0.496 |
|
2010 |
Wang Y, Grainger DW. siRNA knock-down of RANK signaling to control osteoclast-mediated bone resorption. Pharmaceutical Research. 27: 1273-84. PMID 20333451 DOI: 10.1007/S11095-010-0099-5 |
0.535 |
|
Show low-probability matches. |